GenSight Biologics Announces its 2021 Financial Calendar

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

GenSight Biologics announces the partial conversion of convertible bonds and full exercise of share warrants by Kreos Capital

GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

Article – EN

GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency

GenSight Biologics successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

GenSight Biologics launches a capital increase of approximately €25 million by means of an accelerated bookbuilding process

GenSight Biologics Reports Cash Position as of September 30, 2020 and Provides Operational Update

GenSight Biologics Appoints Elsy Boglioli to its Board of Directors